Physiogenex has developed a method for NASH screening that can be implemented in three weeks. The control drugs are ezetimibe and liraglutide.
Compliant with GLP and international regulatory guidelines! Providing suitable assays accurately and quickly!
From basic research to human clinical trials!
Purification from immunity is carried out at the domestic headquarters! We will respond with a wealth of accumulated technology and experience.
We accommodate everything from small-scale to large-scale! We accept manufacturing for research and commercial purposes.
Desired composition, preparation conditions, and capacity are possible! We also accommodate large-scale preparations and product repackaging.
We also support sterility testing! We provide products that have undergone necessary quality tests and meet the standards.
Domestic manufacturing, stable procurement, transportation cost reduction┃★GMP compliant: from small quantities to large volumes (up to 200L)【Buffer manufacturing service】
Specialized staff from various fields collaborate to create a single work.
We provide services utilizing the latest biotechnology.
We offer contracted services for full drainage toxicity testing.
Providing speedy crystal structure analysis at an affordable price!
A drug efficacy evaluation model for diabetic nephropathy developed in collaboration with Japan's Clea and Physiogenex. It shows significant renal damage pathologically at 17 weeks of age.
Physiogenex's proprietary diet-induced (DIN) NASH mouse model. Evaluation of NASH drug efficacy in an obese and insulin-resistant environment.
Pharmacological evaluation of a diet-induced NASH hamster model with human-like cholesterol metabolism characteristics.
By achieving consistent DS and DP manufacturing within the same facility, the need for multiple contract management, material transportation, and technology transfer is minimized! [Exhibiting at BioPharma Expo]